These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 26099532)

  • 1. Design, synthesis and evaluation of novel anti-HCV molecules that deliver intracellularly three highly potent NS5A inhibitors.
    Boucle S; Tao S; Amblard F; Stanton RA; Nettles JH; Li C; McBrayer TR; Whitaker T; Coats SJ; Schinazi RF
    Bioorg Med Chem Lett; 2015 Sep; 25(17):3711-5. PubMed ID: 26099532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and evaluation of non-dimeric HCV NS5A inhibitors.
    Amblard F; Zhang H; Zhou L; Shi J; Bobeck DR; Nettles JH; Chavre S; McBrayer TR; Tharnish P; Whitaker T; Coats SJ; Schinazi RF
    Bioorg Med Chem Lett; 2013 Apr; 23(7):2031-4. PubMed ID: 23466233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Daclatasvir-like inhibitors of NS5A block early biogenesis of hepatitis C virus-induced membranous replication factories, independent of RNA replication.
    Berger C; Romero-Brey I; Radujkovic D; Terreux R; Zayas M; Paul D; Harak C; Hoppe S; Gao M; Penin F; Lohmann V; Bartenschlager R
    Gastroenterology; 2014 Nov; 147(5):1094-105.e25. PubMed ID: 25046163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resensitizing daclatasvir-resistant hepatitis C variants by allosteric modulation of NS5A.
    Sun JH; O'Boyle DR; Fridell RA; Langley DR; Wang C; Roberts SB; Nower P; Johnson BM; Moulin F; Nophsker MJ; Wang YK; Liu M; Rigat K; Tu Y; Hewawasam P; Kadow J; Meanwell NA; Cockett M; Lemm JA; Kramer M; Belema M; Gao M
    Nature; 2015 Nov; 527(7577):245-8. PubMed ID: 26536115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of antiviral effects of novel NS5A inhibitors in hepatitis C virus cell culture system with full-genome infectious clones.
    Murayama A; Fujiwara K; Yamada N; Shiina M; Aly HH; Masaki T; Muramatsu M; Wakita T; Kato T
    Antiviral Res; 2018 Oct; 158():161-170. PubMed ID: 30118732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect.
    Gao M; Nettles RE; Belema M; Snyder LB; Nguyen VN; Fridell RA; Serrano-Wu MH; Langley DR; Sun JH; O'Boyle DR; Lemm JA; Wang C; Knipe JO; Chien C; Colonno RJ; Grasela DM; Meanwell NA; Hamann LG
    Nature; 2010 May; 465(7294):96-100. PubMed ID: 20410884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of BMS-790052 on hepatitis C virus genotype 4 NS5A.
    Wang C; Jia L; Huang H; Qiu D; Valera L; Huang X; Sun JH; Nower PT; O'Boyle DR; Gao M; Fridell RA
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1588-90. PubMed ID: 22203595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HCV NS5A replication complex inhibitors. Part 3: discovery of potent analogs with distinct core topologies.
    Lopez OD; Nguyen VN; St Laurent DR; Belema M; Serrano-Wu MH; Goodrich JT; Yang F; Qiu Y; Ripka AS; Nower PT; Valera L; Liu M; O'Boyle DR; Sun JH; Fridell RA; Lemm JA; Gao M; Good AC; Meanwell NA; Snyder LB
    Bioorg Med Chem Lett; 2013 Feb; 23(3):779-84. PubMed ID: 23273521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant HCV variants with NS5A from genotypes 1-7 have different sensitivities to an NS5A inhibitor but not interferon-α.
    Scheel TK; Gottwein JM; Mikkelsen LS; Jensen TB; Bukh J
    Gastroenterology; 2011 Mar; 140(3):1032-42. PubMed ID: 21111742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of hepatitis C virus NS5A inhibitors as a new class of anti-HCV therapy.
    Lee C
    Arch Pharm Res; 2011 Sep; 34(9):1403-7. PubMed ID: 21975800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small molecules targeting hepatitis C virus-encoded NS5A cause subcellular redistribution of their target: insights into compound modes of action.
    Targett-Adams P; Graham EJ; Middleton J; Palmer A; Shaw SM; Lavender H; Brain P; Tran TD; Jones LH; Wakenhut F; Stammen B; Pryde D; Pickford C; Westby M
    J Virol; 2011 Jul; 85(13):6353-68. PubMed ID: 21507963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical Profile and Clinical Efficacy of a Novel Hepatitis C Virus NS5A Inhibitor, EDP-239.
    Owens CM; Brasher BB; Polemeropoulos A; Rhodin MH; McAllister N; Peng X; Wang C; Ying L; Cao H; Lawitz E; Poordad F; Rondon J; Box TD; Zeuzem S; Buggisch P; Lin K; Qiu YL; Jiang L; Colvin R; Or YS
    Antimicrob Agents Chemother; 2016 Oct; 60(10):6207-15. PubMed ID: 27503640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HCV NS5A inhibitors disrupt replication factory formation: a novel mechanism of antiviral action.
    Eyre NS; Beard MR
    Gastroenterology; 2014 Nov; 147(5):959-62. PubMed ID: 25265576
    [No Abstract]   [Full Text] [Related]  

  • 14. Daclatasvir inhibits hepatitis C virus NS5A motility and hyper-accumulation of phosphoinositides.
    Chukkapalli V; Berger KL; Kelly SM; Thomas M; Deiters A; Randall G
    Virology; 2015 Feb; 476():168-179. PubMed ID: 25546252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HCV NS5A replication complex inhibitors.
    Gao M; O'Boyle DR; Roberts S
    Curr Opin Pharmacol; 2016 Oct; 30():151-157. PubMed ID: 27643675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors.
    Hernandez D; Zhou N; Ueland J; Monikowski A; McPhee F
    J Clin Virol; 2013 May; 57(1):13-8. PubMed ID: 23384816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic Activity of Combined NS5A Inhibitors.
    O'Boyle DR; Nower PT; Gao M; Fridell R; Wang C; Hewawasam P; Lopez O; Tu Y; Meanwell NA; Belema M; Roberts SB; Cockett M; Sun JH
    Antimicrob Agents Chemother; 2015 Dec; 60(3):1573-83. PubMed ID: 26711745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity and resistance profile of samatasvir, a novel NS5A replication inhibitor of hepatitis C virus.
    Bilello JP; Lallos LB; McCarville JF; La Colla M; Serra I; Chapron C; Gillum JM; Pierra C; Standring DN; Seifer M
    Antimicrob Agents Chemother; 2014 Aug; 58(8):4431-42. PubMed ID: 24867983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis C virus NS5A replication complex inhibitors: the discovery of daclatasvir.
    Belema M; Nguyen VN; Bachand C; Deon DH; Goodrich JT; James CA; Lavoie R; Lopez OD; Martel A; Romine JL; Ruediger EH; Snyder LB; St Laurent DR; Yang F; Zhu J; Wong HS; Langley DR; Adams SP; Cantor GH; Chimalakonda A; Fura A; Johnson BM; Knipe JO; Parker DD; Santone KS; Fridell RA; Lemm JA; O'Boyle DR; Colonno RJ; Gao M; Meanwell NA; Hamann LG
    J Med Chem; 2014 Mar; 57(5):2013-32. PubMed ID: 24521299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combinations of two drugs among NS3/4A inhibitors, NS5B inhibitors and non-selective antiviral agents are effective for hepatitis C virus with NS5A-P32 deletion in humanized-liver mice.
    Doi A; Hikita H; Kai Y; Tahata Y; Saito Y; Nakabori T; Yamada R; Kodama T; Sakamori R; Murayama A; Nitta S; Asahina Y; Suemizu H; Tatsumi T; Kato T; Takehara T
    J Gastroenterol; 2019 May; 54(5):449-458. PubMed ID: 30684016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.